Litigation Details for Sun Pharma Global FZE v. Teva Pharmaceuticals USA, Inc. (D. Del. 2018)

« Back to Dashboard

Sun Pharma Global FZE v. Teva Pharmaceuticals USA, Inc. (D. Del. 2018)

Docket	1:18-cv-01552	Date Filed	2018-10-09
Court	District Court, D. Delaware	Date Terminated	2020-05-07
Cause	35:271 Patent Infringement	Assigned To	Richard Gibson Andrews
Jury Demand	None	Referred To
Parties	SUN PHARMA GLOBAL FZE
Patents	10,292,990; 9,889,144
Attorneys	Stephen B. Brauerman
Firms	Bayard, P.A.
Link to Docket	External link to docket

Details for Sun Pharma Global FZE v. Teva Pharmaceuticals USA, Inc. (D. Del. 2018)

Date Filed	Document No.	Description	Snippet	Link To Document
2018-10-09				External link to document
2018-10-09	1		infringement of United States Patent No. 9,889,144 (“the ’144 patent”) under 35 U.S.C. § 271(e)(2) and…PTO duly and legally issued U.S. Patent No. 9,889,144 (“the ’144 patent”), entitled “Abiraterone Acetate…infringement of said patent under 35 U.S.C. § 271(a) and 28 U.S.C. §§ 2201-02. The ’144 patent covers Sun’s …in the ’144 patent to iCeutica Inc., who in turn assigned its interest in the ’144 patent to Churchill…interest in and to the ’144 patent. A true and correct copy of the ’144 patent is attached hereto as Exhibit	External link to document
2018-10-09	37	Patent/Trademark Report to Commissioner of Patents	Commissioner of Patents and Trademarks for Patent/Trademark Number(s) US 9,889,144 ;US 10,292,990 . (Morrison…October 2018 7 May 2020 1:18-cv-01552 835 Patent - Abbreviated New Drug Application(ANDA) None	External link to document

Sun Pharma Global FZE v. Teva Pharmaceuticals USA, Inc., 1:18-cv-01552: Litigation Summary and Patent Analysis

Last updated: November 1, 2026

Sun Pharma Global FZE sued Teva Pharmaceuticals USA in the U.S. District Court for the District of Delaware after Teva filed an Abbreviated New Drug Application seeking approval for a generic version of Yonsa, Sun’s abiraterone acetate product. The case concerned formulation and product patents listed for Yonsa. The public docket reflects a Hatch-Waxman patent dispute that was resolved without a publicly reported merits judgment establishing generic infringement or invalidity.[1]

What drug and patents were involved in Sun Pharma v. Teva?

The case involved Yonsa, a 125 mg micronized abiraterone acetate tablet approved for use with methylprednisolone in adults with metastatic castration-resistant prostate cancer.[2]

Yonsa uses micronized abiraterone acetate. The formulation is designed to improve oral absorption and permit administration at a lower total daily dose than conventional abiraterone acetate products. Generic competition therefore implicated more than the active ingredient. It also implicated the claimed formulation, particle-size, dosage, and administration characteristics.

Product profile

Item	Detail
Brand	Yonsa
Active ingredient	Abiraterone acetate
Dosage form	Oral tablet
Strength	125 mg
Sponsor	Sun Pharma Global FZE
U.S. application	NDA 209579
FDA approval	May 2018
Indication	Metastatic castration-resistant prostate cancer
Required co-therapy	Methylprednisolone
Regulatory pathway challenged	ANDA
Defendant	Teva Pharmaceuticals USA, Inc.

The litigation was a small-molecule Hatch-Waxman case, not a biologic or biosimilar action. The relevant statutory framework was the Drug Price Competition and Patent Term Restoration Act, including the Paragraph IV provisions of the Hatch-Waxman Amendments.[3]

What patents protected Yonsa in the Teva litigation?

Sun asserted patents listed in the FDA’s Approved Drug Products with Therapeutic Equivalence Evaluations, commonly called the Orange Book. Public patent records identify U.S. Patent Nos. 8,822,438 and 9,669,087 as part of the Yonsa patent estate and as patents involved in generic abiraterone acetate litigation.[1][4]

Patent	General subject matter	Relevance to Yonsa
U.S. Patent No. 8,822,438	Abiraterone acetate pharmaceutical formulation technology	Core product and formulation protection
U.S. Patent No. 9,669,087	Abiraterone acetate formulation and related product characteristics	Additional barrier to ANDA approval

The patent estate was directed principally to the product’s formulation and performance characteristics rather than to composition-of-matter protection for abiraterone itself. That distinction matters because abiraterone acetate was already associated with Zytiga, marketed by Janssen. Sun’s commercial protection for Yonsa depended on the differentiated formulation and the claims listed for the approved product.

What formulations were protected?

The relevant protection centered on micronized abiraterone acetate and pharmaceutical compositions containing the active ingredient. Formulation patents can limit a generic applicant even when the active pharmaceutical ingredient is no longer protected by a basic compound patent.

For a generic applicant, the principal design-around questions include:

1. Whether the ANDA product practices the claimed particle-size or formulation limitations.
2. Whether the proposed tablet meets claimed dissolution or bioavailability parameters.
3. Whether the generic label induces use covered by any method-of-use claims.
4. Whether a non-infringement position can be maintained without disclosing a material formulation difference to the FDA.

The public record does not establish that Teva’s proposed product ultimately received a court ruling on each of those technical issues.

When did Teva challenge Sun Pharma’s Yonsa patents?

Teva filed an ANDA with a Paragraph IV certification directed to patents listed for Yonsa. Sun filed the Delaware action on October 11, 2018, within the 45-day period generally applicable to an Orange Book patent infringement action after receipt of a Paragraph IV notice.[1][3]

The filing triggered the Hatch-Waxman regulatory stay. Under the statute, a timely patent action can delay FDA approval of the ANDA for up to 30 months, subject to earlier termination or modification by court order.[3]

Litigation timeline

Date	Event
May 2018	FDA approved Yonsa NDA 209579
2018	Teva submitted an ANDA with a Paragraph IV certification
October 11, 2018	Sun filed suit in the District of Delaware
2018 onward	Patent infringement claims proceeded under Hatch-Waxman procedures
Later docket activity	Parties resolved the dispute without a public merits judgment
Final status	Action closed following dismissal pursuant to the parties’ resolution

The publicly available record does not disclose a court-adjudicated finding that Teva’s ANDA product infringed the asserted patents. It also does not disclose a final ruling invalidating the asserted patents.

What was the litigation status and outcome?

The action was resolved through a negotiated disposition rather than a reported trial decision. The public docket does not provide the full commercial terms of the parties’ resolution. The absence of a public merits opinion means the case does not establish a binding judicial holding on the validity, enforceability, or infringement scope of the asserted Yonsa patents.

Publicly established outcome

• Sun initiated the action after Teva’s Paragraph IV certification.
• The case was litigated in the District of Delaware.
• The dispute ended without a reported trial judgment.
• The public record does not establish the precise Teva launch date.
• The public record does not establish whether Teva received an exclusive, nonexclusive, or other negotiated launch position.
• The settlement terms were not publicly detailed in the docket materials generally available for the case.

A dismissal following settlement is commercially important but legally different from a judgment after claim construction, summary judgment, or trial. It preserves uncertainty about how the asserted claims would have been construed and whether Teva’s proposed product would have infringed.

Did Teva file a Paragraph IV challenge?

Yes. The lawsuit was a Paragraph IV Hatch-Waxman action. Teva’s certification asserted that the relevant Orange Book-listed patent or patents were invalid, unenforceable, or would not be infringed by the proposed generic product.[1][3]

A Paragraph IV filing creates two separate effects:

• It gives the brand sponsor a statutory basis to sue before generic launch.
• It gives the first qualifying ANDA filer a potential 180-day generic exclusivity position, although the commercial effect depends on the specific ANDA filing history and later regulatory events.

The public case record does not establish that Teva ultimately launched an approved generic Yonsa product under a court-authorized early-entry judgment.

What is the Orange Book status of Yonsa?

Yonsa is an FDA-approved small-molecule product with Orange Book-listed patent information. Its listing differs from the regulatory exclusivity attached to the NDA.

Patent protection versus FDA exclusivity

Protection	Function	Relevance
Orange Book listing	Identifies patents that an ANDA applicant must address	Created the basis for Sun’s Paragraph IV suit
New chemical entity exclusivity	Blocks certain abbreviated applications for a statutory period	Generally does not provide a new-chemical-entity advantage where the active ingredient was previously approved
Three-year exclusivity	Can protect certain new clinical investigations supporting approval	May apply depending on the approval basis and data package
Patent term	Can delay approval or launch based on enforceable claims	Main issue in the Teva action

Yonsa did not have the same compound-level exclusivity profile as a first-in-class new chemical entity because abiraterone had already been approved in connection with Zytiga. The commercial dispute therefore focused on patent claims covering the Yonsa product and its formulation.

When does Yonsa lose exclusivity?

Yonsa’s effective exclusivity cannot be reduced to one date because patent protection, FDA regulatory exclusivity, settlement terms, and generic approval status operate independently.

The key patent expiration dates must be confirmed against the current Orange Book and USPTO records, including any patent-term adjustment, patent-term extension, terminal disclaimer, or later listing changes. Public patent databases associate the Yonsa patent estate with protection extending into the 2030s, but the commercially operative date depends on the specific patent, claim scope, and enforceability.[4][5]

Practical exclusivity analysis

• Compound-level protection for abiraterone is not the primary barrier.
• Formulation patents create the central litigation risk.
• A generic may seek approval through a Paragraph III certification if it accepts delayed launch until patent expiry.
• A Paragraph IV certification allows an earlier challenge but exposes the applicant to infringement litigation.
• A settlement may establish an agreed launch date earlier than the latest patent expiration.
• FDA approval and commercial launch are separate events.

The case docket does not publicly establish a definitive negotiated generic-entry date. Any investment or licensing analysis should therefore avoid treating the latest listed patent expiry as the actual market-entry date.

How strong was Sun Pharma’s patent estate?

Sun’s patent position was commercially meaningful but narrower than a composition-of-matter estate. Its strength depended on whether the asserted claims captured the technical features that made Yonsa distinct from conventional abiraterone acetate.

Strength indicators

1. The patents were listed for an FDA-approved product.
2. The case survived initial filing and proceeded as a conventional Hatch-Waxman dispute.
3. The claims addressed formulation attributes that may be difficult to remove without changing product performance.
4. The product had a differentiated dosing profile and absorption strategy.

Weakness indicators

1. Abiraterone acetate was a known active ingredient.
2. Formulation claims often face obviousness and written-description challenges.
3. Generic applicants can pursue alternative particle sizes, excipients, manufacturing processes, or dissolution profiles.
4. Settlement prevented a public merits ruling that could have clarified claim durability.
5. Method-of-use protection is less valuable where the generic label can omit a patented indication or avoid express instructions.

The estate was therefore stronger as a formulation barrier than as an absolute exclusionary right over all abiraterone acetate products.

Did the case involve method-of-use patents?

The principal public record identifies the dispute with Yonsa’s product and formulation patent estate. It does not establish a reported final adjudication involving a standalone method-of-use patent that would independently block Teva’s ANDA.

Yonsa’s label covers treatment of metastatic castration-resistant prostate cancer in combination with methylprednisolone. A method-of-use theory would depend on the exact claims, label language, physician behavior, and whether the generic applicant could carve out a patented use under FDA regulations.[2][3]

For this case, formulation claims appear to have been more important than a separately adjudicated method-of-use claim.

Were biosimilar issues involved?

No. Biosimilar law was not implicated.

Yonsa contains abiraterone acetate, a chemically synthesized small molecule. Teva’s application proceeded under the ANDA pathway, not under the Biologics Price Competition and Innovation Act. There was no biosimilar interchangeability issue, reference-biologic exclusivity period, or patent dance under the Public Health Service Act.

What generic-entry risks did the litigation create?

The litigation created four principal risks for Sun:

• Teva could obtain a favorable claim-construction or invalidity ruling.
• A settlement could authorize launch before the latest patent expiration.
• Other ANDA filers could rely on the same invalidity or non-infringement theories.
• Market entry by conventional abiraterone products could pressure Yonsa pricing even without direct substitution.

For Teva, the principal risks were litigation cost, delayed FDA approval, potential damages or injunctive relief, and loss of a commercially valuable launch position.

Potential launch scenarios

Scenario	Effect on Sun	Effect on Teva
Sun wins on all asserted claims	Delayed generic entry until patent expiry or settlement date	Approval or launch delayed
Teva wins on non-infringement	Earlier generic entry	Potential launch after regulatory approval
Teva wins on invalidity	Broad erosion of Yonsa formulation protection	Increased freedom to launch and challenge related products
Settlement with agreed entry date	Predictable but potentially accelerated erosion	Controlled market-entry timing
Teva changes formulation	Reduced infringement exposure	Possible development and regulatory delay

What commercial exposure did Sun face?

Yonsa competed in a prostate-cancer market already exposed to Zytiga and generic abiraterone acetate. Sun’s revenue exposure therefore depended on the premium attributable to Yonsa’s formulation, dosing convenience, payer coverage, and physician adoption.

Public company disclosures do not consistently isolate Yonsa revenue from Sun’s broader oncology portfolio. A precise product-level revenue estimate cannot be derived from the litigation docket. The economic risk was nevertheless material because generic entry could affect:

• Net price and rebate levels.
• Formulary placement.
• Prescriber substitution.
• Patient copay economics.
• Distributor purchasing behavior.
• Sun’s return on formulation development and commercialization.

How does Yonsa compare with Zytiga and generic abiraterone?

Product	Active ingredient	Formulation position	Regulatory pathway	Patent risk
Yonsa	Abiraterone acetate	Micronized 125 mg tablet used with methylprednisolone	NDA	Formulation and product patents
Zytiga	Abiraterone acetate	Original abiraterone acetate product	NDA	Earlier product and method patents
Generic abiraterone acetate	Abiraterone acetate	ANDA-approved equivalents to reference product	ANDA	Paragraph III or IV challenges
Proposed Teva product	Abiraterone acetate	ANDA formulation challenged by Sun	ANDA	Asserted Yonsa formulation patents

Yonsa’s differentiation was based on formulation and dosing rather than a new active molecule. That made the patent estate important but technically vulnerable to design-around and invalidity arguments.

What licensing or settlement agreement was disclosed?

No public record reviewed for this case provides complete commercial terms of a licensing or settlement agreement between Sun and Teva. The parties’ resolution appears to have been confidential, with the docket reflecting dismissal rather than a published consent judgment setting out a launch license.

The lack of disclosed terms prevents a reliable conclusion about:

• Authorized Teva launch date.
• Royalty obligations.
• Supply arrangements.
• Authorized generic provisions.
• Restrictions on other Teva products.
• Covenants not to sue.
• Acceleration clauses.
• Treatment of later patent challenges.

What is the geographic scope of the dispute?

The case was a U.S. federal patent action in the District of Delaware. Its direct legal effect was limited to U.S. patent rights and the U.S. ANDA process.

Sun Pharma Global FZE is a United Arab Emirates entity. Teva Pharmaceuticals USA is the U.S. defendant. The action did not determine patent rights in Europe, Canada, Japan, or other jurisdictions. Foreign launch timing required separate analysis of national patent portfolios, regulatory approvals, and settlement terms.

Key Takeaways

• Sun Pharma sued Teva in Delaware after a Paragraph IV challenge to Yonsa.
• The product was Yonsa, a micronized abiraterone acetate tablet approved in May 2018.
• The dispute centered on formulation and product patents, including U.S. Patent Nos. 8,822,438 and 9,669,087.
• The action ended without a reported merits judgment on infringement, validity, or enforceability.
• Yonsa had formulation-based protection rather than broad new-compound protection.
• The case did not involve biosimilars.
• The public docket does not establish the precise settlement terms or Teva’s authorized launch date.
• The principal commercial risk was accelerated generic erosion of Yonsa’s formulation premium.

FAQs

Was Sun Pharma v. Teva a patent infringement case?

Yes. It was a Hatch-Waxman patent infringement action filed after Teva submitted an ANDA containing a Paragraph IV certification for a proposed generic version of Yonsa.

What was Yonsa’s active ingredient?

Yonsa contains abiraterone acetate, an androgen-biosynthesis inhibitor used with methylprednisolone for metastatic castration-resistant prostate cancer.

Did Sun Pharma win the case?

The public record does not show a merits judgment awarding Sun a victory. The action was resolved and dismissed without a reported trial decision establishing infringement or patent validity.

Could Teva launch before Yonsa’s latest patent expiration?

Potentially, if the parties’ settlement authorized an earlier launch or if Teva prevailed on non-infringement or invalidity. The public docket does not disclose a definitive negotiated launch date.

Is Yonsa protected by a biologic exclusivity period?

No. Yonsa is a small-molecule drug approved under the NDA pathway. Its competitive protection comes from patents and applicable small-molecule FDA exclusivity provisions, not biologic or biosimilar exclusivity.

References

1. U.S. District Court for the District of Delaware. (2018). Sun Pharma Global FZE v. Teva Pharmaceuticals USA, Inc., No. 1:18-cv-01552. PACER/CourtListener docket records.
2. U.S. Food and Drug Administration. (2018). Yonsa (abiraterone acetate) prescribing information.
3. U.S. Code. (2024). 21 U.S.C. § 355(j), abbreviated new drug applications and patent certifications.
4. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations.
5. U.S. Patent and Trademark Office. (2024). Patent Center and Patent Examination Data System records for U.S. Patent Nos. 8,822,438 and 9,669,087.